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We conducted this study to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a
first-line treatment for patients with advanced gastric cancer. In all, 52 patients received courses of docetaxel 60mgm
 2 intravenously
(i.v.) for 1h and then cisplatin 75mgm
 2 i.v. for 2h on day 1. Oral UFT at 400–600mgday
 1, as determined by body surface area,
and leucovorin at 75mgday
 1 were administered for 21 consecutive days from day 1, and this was followed by a 7-day drug-free
interval. A total of 225 courses were administered, and the median number of courses per patient was four. Four complete responses
(7.7%) and 22 partial responses (42.3%) were achieved, giving an overall response rate of 50% (95% Confidence Interval: 36.4–
63.6%). The major toxicity was neutropenia, which reached grade 3/4 in 36 patients (69.3%). Grade 3/4 nausea and vomiting was
observed in 12 patients (23.1%). Median time to progression was 22 weeks (4 to 156þ weeks), median survival duration was 48
weeks (4 to 156þ weeks), and median response duration was 24 weeks (6–152 weeks). We conclude that docetaxel, cisplatin, oral
UFT, and leucovorin combination chemotherapy is effective and tolerable for the treatment of advanced gastric cancer.
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Gastric cancer is one of the most common malignancies in Korea
(Bae et al, 2002) and the second most common cause of cancer-
related death worldwide (Boring et al, 1994). Despite a decreasing
incidence of gastric cancer in the West, the incidence of
adenocarcinoma in cardia and at the gastro-oesophageal junction
has increased, and 5-year survival for advanced gastric cancer
remains poor (Wilke et al, 1990). As many patients continue to
present with an advanced stage (Karpeh et al, 2001), systemic
chemotherapy remains the main treatment modality for this
disease. Several drugs have shown significant activity against
gastric cancer as single agents. These include doxorubicin,
cisplatin, and 5-fluorouracil (5-FU), which produce response rates
between 19 and 86% (Preusser et al, 1988; Findlay and Cunningham,
1993). Combination regimens of these drugs have also shown
response rates of 30–50% in phase II studies (Preusser et al, 1988;
Kim et al, 1993). At present, the 5-FU/cisplatin (FP) combination is
the most widely used regimen against advanced gastric cancer.
Phase II studies of the 5-FP combination reported a 40–51%
response rate in previously untreated patients (Kim et al, 1993;
Rougier et al, 1994). FP regimen also produced a significantly
higher response rate and a longer time to progression than the
FAM (5-FU/doxorubicin/mitomycin) or 5-FU regimens. However,
these high response rates did not translate into survival benefits
(Kim et al, 1993).
To augment the efficacy of the FP regimen, new chemothera-
peutic agents have been added, such as taxane, CPT-11, and
oxaliplatin. In our previous study, the paclitaxel and 5-FP
combination produced a 51% objective response, which suggests
that taxane is efficacious in gastric cancer (Kim et al, 1999).
Docetaxel, a semi-synthetic analogue of paclitaxel, was reported to
offer superior response rates and a longer time to progression
when added to the FP regimen (5-FU/cisplatin) than FP alone in a
randomised phase III trial (Ajani et al, 2003). It was also reported
that the long-term oral administration of UFT could be as effective
as intravenous (i.v.) 5-FU in patients with colorectal cancer
(Carmichael et al, 2002, Douillard et al, 2002). This is supported by
our previous experience, namely, that oral UFT/leucovorin was
effective in advanced gastric cancer with a response rate of 27%,
and tolerable toxicity (Kim et al, 1997). Based on these results, we
designed a phase II study to evaluate the efficacy of a combined
docetaxel-modified FP regimen for the treatment of advanced
gastric cancer. To modify the FP regimen, we used oral UFT
instead of a 5-FU i.v. infusion and added leucovorin to moderate
the antitumour effect of UFT.
PATIENTS AND METHODS
Patients
Between September 2001 and September 2003, 52 patients with
histologically proven gastric adenocarcinoma, and locally unre-
sectable, recurrent, or metastatic disease were enrolled at the Korea
University Medical Center (KUMC). Patients with measurable
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sdisease, a performance status p2, and a life expectancy of at least 8
weeks were accepted. Laboratory acceptance parameters included
a white blood cell count of 44.0 10
3l
 1, an absolute neutrophil
count of 41.5 10
3l
 1, platelets 4100 10
3l
 1, serum transami-
nase o3 the upper normal limit (UNL), and bilirubin and
creatinine (Cr) values of o1.5 UNL. Contraindications to entry
included an active infectious process, an active heart disease,
central nervous system involvement, or any concomitant second
primary cancer. Patients who had received previous chemother-
apy, except adjuvant chemotherapy, were also excluded. Written
informed consent was obtained from all patient study subjects, and
the study protocol was approved by the institutional review board
of KUMC.
Treatment
On day 1, docetaxel at a dose of 60mgm
 2 was administered by
i.v. infusion over 1h. After i.v. hydration for 2h to prevent
nephrotoxicity, cisplatin was administered at 75mgm
 2 i.v. over
2h. These administrations were repeated every 4 weeks. Oral UFT
and leucovorin were administered for 21 consecutive days from
day 1 to day 21, and this was followed by a 7-day treatment-free
period. The total daily dose of UFT (determined by tegafur dosage)
was set at three levels according to body surface area (41.75m
2:
600mgday
 1; between 1.75 and 1.25m
2: 500mgday
 1; o1.25m
2:
400mgday
 1) and it was divided into three doses, which were
administered orally every 8h. It should be noted that UFT was
supplied in capsule form, and contained 100mg of tegafur and
225mg per capsule. The total daily dose of oral leucovorin (75mg)
was divided into three doses, and these were administered every
8h regardless of body surface area.
Dose modification for adverse events
Toxicity was evaluated before each treatment cycle as described in
the National Cancer Institute Common Toxicity Criteria (NCI
CTC) version 3.0. In cases of grade 3/4 neutropenia of over 5 days
duration, or febrile neutropenia, or a platelet count of
o50 10
3l
 1, docetaxel and cisplatin dosages were reduced by
25%. In cases of grade 3/4 gastrointestinal toxicity, the UFT dosage
was decremented by 100 mgday
 1. UFT and leucovorin were
withheld in cases of severe nonhaematologic toxicity, and restarted
after symptom resolution. When severe toxicity was noticed at the
time of a scheduled administration, treatment was postponed for 1
week until the toxicity resolved. If drug administration was delayed
for more than 2 weeks, the subject was excluded from the study.
This schedule was repeated 4 weekly until tumour progression or
until treatment intolerance developed.
In addition to the above, dolasetron (100mg) was administered
before cisplatin infusion, and lorazepam (0.5mg) was adminis-
tered twice on day 1 to prevent delayed emesis, and oral
metoclopropamide was prescribed during UFT and leucovorin
administration.
Evaluation
All patients were examined clinically prior to enrollment, and
received laboratory evaluations which included: a complete blood
cell (CBC) count, electrolytes, blood urea nitrogen (BUN), Cr, liver
function test (LFT), and carcinoembronic antigen (CEA). Upper
gastrointestinal endoscopy, abdominal computed tomography, and
other appropriate procedures were also performed. CBC counts
were carried out on days 7, 14, and 28 of every cycle. Chest
radiography and laboratory tests including LFT, BUN, Cr,
electrolytes, and CEA were performed on day 28 of every cycle.
An examination of measurable parameters, such as abdominal
computed tomography or chest computed tomography, was used
to evaluate treatment response after every two courses of
treatment. The World Health Organization (WHO) criteria were
adopted (Miller et al, 1981) to measure response, which was
assessed by the investigators.
Statistical analysis
All enrolled patients were included in the intention-to-treat
analysis of regimen efficacy. The trial was conducted using
response rate as the primary end point, and a response rate of
40–50% was anticipated for this regimen as a first-line
chemotherapy for advanced gastric cancer. A response rate of
30% was considered as the minimum level of interest in this
patient population. Given a true response rate of 50% among 50
patients, the present study provided a 99.67% chance of our being
able to determine that the actual response rate exceeded 30%. Time
to progression, overall survival, and response duration were
secondary end points in Kaplan–Meier analysis. Response
duration was defined as the interval between response onset until
evidence of progression. Time to progression and overall survival
were calculated from the date of study commencement until
progression or until the date of the last follow-up or death,
respectively.
RESULTS
Patients characteristics
Median patient age was 56 years, with a range of 19–77 years
(Table 1). In all, 10 patients had a past history of surgery (curative
intent in eight and palliative intent in two). One patient had
received postoperative adjuvant chemotherapy and one patient
intraperitoneal chemotherapy. However, more than 6 months had
lapsed between this prior chemotherapy and enrollment into the
present study. In total, 42 patients were treatment naive. Median
follow-up duration was 11.1 months, and 93, 92.8, and 90.6% of the
intended doses of docetaxel, cisplatin, and oral UFT/leucovorin
were delivered, respectively.
Response to chemotherapy
The 52 enrolled patients received 225 courses of chemotherapy
with a median number of courses per patient of four, and a range
of 1–8 (Table 2). Five patients who could not complete the second
Table 1 Patient characteristics
Total no. of patients 52
No. of nonevaluable patients 5
Median age in year 56
Range 19–77
Male/female 37/15
ECOG performance status
04
13 9
29
Site of metastasis
Lymph node 34
Liver 15
Lung 3
Previous treatment
None 42
Operation 10
Palliative/curative 2/8
Chemotherapy 2
IP/adjuvant 1/1
ECOG¼Eastern cooperative oncology group.
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scycle of treatment were not evaluable, three patients were lost at
follow-up, and two patients were lost due to treatment-related
mortalities (one with sepsis and acute renal failure after the first
cycle of treatment and the other patient with grade 4 hepatitis and
grade 4 diarrhoea after the second cycle of treatment). Four
patients achieved complete response (7.7%) and 22 patients partial
response (42.3%). Thus, the overall objective response rate was
50.0% (95% confidence interval (CI), 36.4–63.6%) with a median
response duration of 24 weeks (95% CI: 19–29 weeks; range: 6–
152 weeks). In all, 17 patients had stable disease and four patients
showed disease progression. No complete response was observed
among 18 patients with liver or lung metastasis, but four cases of
complete response were observed among 34 patients with
lymphatic metastasis. No significant difference was observed
between partial response and stable disease rates with respect to
disease extent. Median time to progression was 22 weeks (95% CI:
16–28 weeks; range: 4 to 156þ weeks), and median survival
duration was 48 weeks (95% CI: 25–70 weeks; range: 4 to 156þ
weeks) (Figure 1). Four patients with complete response had
measurable lymph-node involvement, and surgery was attempted
in three of these patients. Although two of the three achieved a
pathological complete response, complete resection failed in the
other patient, who subsequently developed lung metastasis.
Toxicity
The main toxicities encountered using this docetaxel/cisplatin/
UFT/leucovorin combinatorial therapy were neutropenia and
nausea and vomiting (Table 3). Grade 3 or 4 neutropenia occurred
in 16 (30.8%) and 20 (38.5%) patients, respectively, and grade 3 or
4 thrombocytopenia was observed in two (3.8%) and one patient
(1.9%), respectively. A total of 18 patients required docetaxel and
cisplatin dose modification. Of these, the most common cause of
dose reduction was prolonged neutropenia or neutropenic fever in
16, hepatitis in one, and early diarrhoea (earlier than day 8) in one.
In all, 18 patients required a UFT dose reduction. The most
common causes of these dose reductions were: grade 3 or 4 nausea
or vomiting in 10, followed by grade 3 or 4 diarrhoea in three. Four
patients had multiple toxicities, and required UFT dose modifica-
tion (one patient had grade 4 mucositis with grade 3 diarrhoea, one
had grade 4 mucositis with grade 4 diarrhoea, one had grade 3
mucositis and grade 3 diarrhoea, and the fourth had grade 3
diarrhoea and grade 3 nausea). Grade 2 hepatotoxicity was
observed in one patient who remained on a modified UFT dose
from the second cycle of treatment. There were three treatment-
related mortalities: one patient with grade 3 nausea and grade 3
diarrhoea during the first treatment cycle was lost to follow-up and
did not proceed to the next cycle of treatment, another patient died
during the first cycle due to severe diarrhoea with grade 4
hepatitis, and the third succumbed to sepsis and acute renal
failure. In all, 10 patients required a dose modification of all three
anticancer drugs due to multiple adverse effects. Thus, of the 225
courses administered, 56 courses involved a 25% dosage reduction,
and seven courses involved more than a 25% dosage reduction.
DISCUSSION
Docetaxel, a semisynthetic analogue of paclitaxel, continues to
show promise as an antigastric cancer agent (Sulkes et al, 1994,
Einzig et al, 1996). Several phase II studies in Europe and USA
have reported fairly consistent objective response rates for
docetaxel (100mgm
 2; 3 weekly) ranging from 17 to 24%. Two
Japanese studies adopted 60mgm
 2, 3 weekly of docetaxel for the
second-line treatment of advanced gastric cancer and achieved
response rates of 20 and 22% (Taguchi et al, 1998; Mai et al, 1999).
Moreover, in a study of Korean advanced gastric cancer patients, a
15.9% response rate was obtained with single-agent docetaxel at
75mgm
 2 every 3 weeks (Bang et al, 2002). Synergism between
docetaxel and cisplatin was suggested by the Swiss Group for
Clinical Cancer Research (SAKK) and by the European Institute for
Oncology (EIO) in Milan (Roth et al, 2000; Kettner et al, 2001).
These two reports found that the docetaxel (85mgm
 2) and
Table 2 Treatment response shown by gastric cancer patients
Total no. of chemotherapy cycle 225
Median 4
Range 1–8
Dose delivery
Docetaxel 93.0%
Cisplatin 92.8%
UFT/leucovorin 90.6%
Response (%) (n¼52)
CR 4 (7.7%)
PR 22 (42.3%)
SD 17 (32.7%)
PD 4 (7.7%)
NE 5 (9.6%)
Overall response (95% CI) 50.0% (36.4–63.6%)
Median time to progression, week, range 22 (4 to 156+)
Median survival duration, week, range 48 (4 to 156+)
Median response duration, week, range 24 (6–152)
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼
progressive disease; NE¼not evaluable.
Survival time (weeks)
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Figure 1 Patient (N¼52) survival duration.
Table 3 Major toxicities – NCI CTC version 2.0 (N¼52)
Number of patients (%)
Toxicity Grade I/II III IV
Neutropenia 5 (9.6) 16 (30.8) 20 (38.5)
Thrombocytopenia 2 (3.8) 2 (3.8) 1 (1.9)
Anaemia 10 (19.2) 0 1 (1.9)
Mucositis 3 (5.8) 1 (1.9) 2 (3.8)
Diarrhoea 5 (9.6) 3 (5.8) 6 (11.5)
Nausea/vomiting 7 (13.5) 12 (23.1) 0
Hepatotoxicity 1 (1.9) 0 1 (1.9)
Alopecia 27 (45) 0 0
NCI CTC¼National Cancer Institute Common Toxicity Criteria.
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scisplatin (75mgm
 2) combination produced a response rate of
52% in 48 patients, a median time to progression of 6.6 months,
and a median overall survival time of 9 months by intention-to-
treat analysis. In addition, although therapeutic efficacy was not
the primary objective, a phase I study of weekly docetaxel, and
24-h infusion of high-dose fluorouracil and leucovorin, and
cisplatin produced a response in 16 of 26 (61.5%, two complete
responses and 14 partial responses) evaluable advanced gastric
cancer patients (Chen et al, 2002).
To augment the therapeutic effect of docetaxel/cisplatin, a
randomised phase II study compared the combination docetaxel
(75mgm
 2), cisplatin (75mgm
 2), and 5-FU (750mgm
 2)
with docetaxel (85mgm
 2) and cisplatin (75mgm
 2) (Roth
and Ajani, 2003). The study showed that the addition of 5-FU
increased the response rate (44% vs 30%). Another randomised
phase II study compared a combination of docetaxel and cisplatin
(DC) with docetaxel, cisplatin, and 5-FU (DCF). By intention-to-
treat analysis, the response rate of DC was 28% and that of
DCF was 43%. This higher response rate achieved by DCF led
to a comparative phase III clinical trial against cisplatin plus
5-FU (CF) (Roth and Ajani, 2003). In an interim analysis, DCF
was found to have an extended time to progression (5.2 vs 3.7
months) and an increased response rate (39 vs 23%) (Ajani et al,
2003). Thus, the docetaxel/cisplatin/5-FU combination may
emerge as the standard regimen for the treatment of advanced
gastric cancer.
In our study, oral UFT was used instead of i.v. 5-FU. Oral UFT is
known to generate plasma 5-FU levels that are similar to those of
i.v. 5-FU, and oral UFT can produce up to 10-fold higher 5-FU
concentrations in tumour tissue than in normal tissue. Further-
more, oral UFT has several advantages over i.v. 5-FU in terms of its
clinical application. First, UFT can be administered enterally,
which promotes compliance and maintains a constant plasma level
of 5-FU. Second, it can be discontinued whenever severe toxicity
develops, which prevents further toxicity-associated deterioration.
Moreover, after toxicity subsidence, patients can restart the
schedule. During the past decade, it has been recognised that
leucovorin modulates 5-FU and enhances antitumour efficacy
(Buroker et al, 1994), and in our previous study, oral UFT/
leucovorin was found to have a role in the palliative chemotherapy
of advanced gastric cancer (Kim et al, 1997).
In the present study, neutropenia was the main haematological
toxicity, and grade 3 or 4 neutropenia was observed in 16 (30.8%)
and 20 (38.5%) patients, respectively. Febrile neutropenia devel-
oped in seven patients, and of these six recovered with support
from granulocyte colony-stimulating factor, and the dose was
subsequently reduced. The remaining patient did not receive a
subsequent course due to a sepsis-related mortality. Severe
neutropenia was also observed in a SAKK and EIO study (Roth
et al, 2000), and another study also reported neutropenia as the
major dose-limiting toxicity; 45% showed grade 3–4 neutropenia,
and among these, two episodes of febrile neutropenia occurred
(Chen et al, 2002). In the present study, nonhaematological toxicity
was moderate, and grade 3 nausea and vomiting developed in 12
(20%) patients, and grade 3/4 diarrhoea or mucositis developed in
less than 10% of patients. These nonhaematologic toxicities were
successfully managed by symptomatic treatment. Nine patients
developed grade 3 or 4 diarrhoea during oral UFT and leucovorin
treatment, which necessitated oral UFT and leucovorin treatment
cessation. However, after symptomatic relief, treatment was
restarted in seven of the nine. Of the two remaining patients,
one died after the first treatment cycle and one patient was lost to
follow-up. The following course of treatment was restarted in the
seven with a dose reduction of UFT at the minus one level (a
decrement of 100 mgday
 1). These results suggest that the
regimen containing oral UFT has a better toxicity profile than
DCF (Ajani et al, 2003), and support previous findings of studies
that reported that the long-term oral administration of UFT might
be as useful as i.v. 5-FU in patients with colorectal cancer
(Carmichael et al, 2002, Douillard et al, 2002).
The present study demonstrates that our regimen is highly
effective and has a feasible toxicity profile against advanced gastric
cancer with a 50.0 % overall response rate and a 48-week median
survival. Owing to the 1-day infusion schedule, this regimen can be
administered on an outpatient basis without disrupting daily life.
We conclude that the oral UFT/leucovorin/docetaxel/cisplatin
combination is likely to be active against advanced gastric cancer.
Nevertheless, a randomised phase III trial is warranted to compare
this regimen with docetaxel/cisplatin/i.v. 5-FU.
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